Health and Happiness (H&H) International (1112) Investor Day 2026 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2026 summary
13 May, 2026Strategic partnership and business overview
Emphasis on a 15-year strategic partnership with Isigny, a key supplier and partner, underpinning growth in infant milk formula (IMF) and global expansion, especially in China and France.
IMF is the second-largest business segment, representing about one-third of total revenue, and is a critical growth pillar.
Biostime brand has achieved top market positions: number five in China and number one in France's pharmacy channel for organic IMF, with nearly 50% market share.
The partnership is built on mutual trust, quality, and long-term investment, not just supply contracts.
Isigny’s cooperative model ensures quality, sustainability, and reinvestment in operations and farmers.
Financial performance and guidance
Q1 group revenue grew 34% year-on-year, with Baby Nutrition up over 60% and IMF up over 72%.
Pediatric probiotics and kids nutrition returned to strong double-digit growth at 23%.
Adult Nutrition and Care (ANC) business grew 26% overall, with China up 33% and Australia up 16.5%.
Pet nutrition, mainly Zesty Paws in North America, grew 17% and now accounts for 11.6% of group revenue.
Strong cash reserves (2.1 billion RMB) and significant deleveraging achieved, with over 300 million RMB debt reduction in Q1 and a full-year target of 700 million RMB.
Product innovation and market strategy
Biostime IMF’s growth is driven by high-quality, science-based formula design, including the launch of HMO products with the highest 2'-FL dosage in China.
The brand focuses on consumer-centric communication, targeting new-generation mothers and early-stage consumer recruitment.
The unique Normandy cow breed provides milk with higher A2 protein and OPO levels, differentiating the product from competitors.
Manufacturing uses patented spray-drying technology for superior dissolving speed and quality.
The company maintains a strong focus on quality, traceability, and sustainability, including B Corp certification and environmental initiatives.
Latest events from Health and Happiness (H&H) International
- Double-digit revenue and profit growth, lower leverage, and market leadership in key segments.1112
H2 202514 May 2026 - Q1 2026 revenue rose 34.4% with strong growth in nutrition and robust cash flow; outlook positive.1112
Q1 2026 TU24 Apr 2026 - Revenue up 4.9% with strong China growth, higher adjusted net profit, and interim dividend declared.1112
H1 20253 Feb 2026 - Revenue and profit fell as IMF declined, but nutrition supplements and cash flow improved.1112
H1 202423 Jan 2026 - Supplements now drive 67.7% of revenue as IMF falls, with 2025 set for recovery.1112
H2 20247 Jan 2026